You are here

NIH Launches Trial of Investigational Vaccine for Genital Herpes

Study will be completed in 2016 (November 8)

Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes infection. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is sponsoring the phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Maryland.

The study will test an investigational herpes simplex virus-2 (HSV-2) vaccine candidate, called HSV529, for safety and for the ability to generate an immune response. The investigational vaccine is manufactured by Sanofi Pasteur.

The clinical trial is expected to enroll 60 adults aged 18 to 40 years, who will be divided into three groups of 20 participants each. The first group will consist of participants who have been previously infected with HSV-2 and HSV-1 or only with HSV-2; the second group will have individuals who had been infected only with HSV-1; and the third group will consist of those who have not been infected with HSV-1 or HSV-2.

Within each of the three groups, researchers will randomly assign participants to receive three doses (0.5 mL each) of the HSV529 vaccine (15 participants) or a saline-based placebo vaccine (five participants). The three vaccinations will occur at study enrollment and again 1 month and 6 months later. Researchers will follow the participants for 6 months after they have received their last dose of vaccine. Blood samples will be used to evaluate the candidate vaccine’s ability to stimulate immune responses to HSV-2, including the production of virus-specific antibodies and T-cell responses.

The study is expected to be completed by October 2016.

Source: NIH; November 8, 2013.

Recent Headlines

Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs